Effect of one-year dextromethorphan/quinidine treatment on management of respiratory impairment in amyotrophic lateral sclerosis

Sancho, Jesús; Ferrer, Santos; Burés, Enric; Palencia, José Luis Díaz; Torrecilla, Teresa; Signes-Costa, Jaime; Servera, Emilio

doi:10.1016/j.rmed.2021.106536

Cited by 3 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the first FDA-approved drug for the treatment of PBA, dextromethorphan/quinidine enhanced the bulbar function (speech, swallowing and salivation) in ALS individuals in a randomized clinical trial [ 256 , 257 ], and several other trials have been completed (NCT01806857, NCT03883581, NCT01806857 and NCT00573443). However, in the long term, the drug does not affect the deterioration of bulbar function or avert non-invasive respiratory management in ALS individuals [ 258 ].…”

Section: Sigma Receptor Ligands For Neurological Diseasementioning

confidence: 99%

Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders

Malar,

Thitilertdecha,

Ruckvongacheep

et al. 2023

CNS Drugs

View full text Add to dashboard Cite

The sigma-1 receptor is a 223 amino acid-long protein with a recently identified structure. The sigma-2 receptor is a genetically unrelated protein with a similarly shaped binding pocket and acts to influence cellular activities similar to the sigma-1 receptor. Both proteins are highly expressed in neuronal tissues. As such, they have become targets for treating neurological diseases, including Alzheimer’s disease (AD), Huntington’s disease (HD), Parkinson’s disease (PD), multiple sclerosis (MS), Rett syndrome (RS), developmental and epileptic encephalopathies (DEE), and motor neuron disease/amyotrophic lateral sclerosis (MND/ALS). In recent years, there have been many pre-clinical and clinical studies of sigma receptor (1 and 2) ligands for treating neurological disease. Drugs such as blarcamesine, dextromethorphan and pridopidine, which have sigma-1 receptor activity as part of their pharmacological profile, are effective in treating multiple aspects of several neurological diseases. Furthermore, several sigma-2 receptor ligands are under investigation, including CT1812, rivastigmine and SAS0132. This review aims to provide a current and up-to-date analysis of the current clinical and pre-clinical data of drugs with sigma receptor activities for treating neurological disease.

show abstract

Section: Sigma Receptor Ligands For Neurological Diseasementioning

confidence: 99%